Drug Standards
- (2)
- (4)
- (1)
- (3)
- (3)
- (665)
- (3)
- (27)
- (1)
- (6)
- (27)
- (61)
- (24)
- (1)
- (2)
- (35)
- (367)
- (45)
- (1)
- (2)
- (1)
- (5)
- (5)
- (4)
- (2)
- (7)
- (1)
- (5)
- (4)
- (3)
- (3)
- (1)
- (3)
- (2)
- (2)
- (1)
- (2)
- (3)
- (4)
- (2)
- (2)
- (1)
- (1)
- (3)
- (1)
- (1)
- (1)
- (4)
- (1)
- (1)
- (1)
- (1)
- (4)
- (3)
- (1)
- (1)
- (2)
- (5)
- (1)
- (2)
- (4)
- (1)
- (1)
- (3)
- (5)
- (3)
- (1)
- (2)
- (1)
- (1)
- (1)
- (3)
- (1)
- (1)
- (3)
- (4)
- (2)
- (2)
- (1)
- (4)
- (4)
- (5)
- (3)
- (1)
- (1)
- (1)
- (1)
- (1)
- (1)
- (1)
- (1)
- (1)
- (1)
- (1)
- (3)
- (4)
- (3)
- (1)
- (4)
- (1)
- (2)
- (1)
- (5)
- (2)
- (2)
- (1)
- (5)
- (7)
- (3)
- (1)
- (1)
- (1)
- (4)
- (1)
- (3)
- (1)
- (4)
- (1)
- (8)
- (2)
- (1)
- (5)
- (13)
- (1)
- (2)
- (1)
- (1)
- (1)
- (2)
- (4)
- (1)
- (5)
- (1)
- (1)
- (2)
- (1)
- (6)
- (2)
- (1)
- (2)
- (2)
- (1)
- (3)
- (1)
- (2)
- (2)
- (1)
- (1)
- (3)
- (3)
- (1)
- (1)
- (2)
- (3)
- (1)
- (1)
- (1)
- (2)
- (4)
- (3)
- (1)
- (1)
- (5)
- (3)
- (2)
- (5)
- (1)
- (3)
- (1)
- (1)
- (1)
- (1)
- (1)
- (2)
- (1)
- (1)
- (1)
- (2)
- (2)
- (1)
- (2)
- (2)
- (4)
- (4)
- (1)
- (2)
- (2)
- (1)
- (2)
- (4)
- (5)
- (2)
- (1)
- (3)
- (2)
- (2)
- (11)
- (1)
- (2)
- (2)
- (2)
- (5)
- (5)
- (4)
- (2)
- (4)
- (2)
- (1)
- (2)
- (5)
- (2)
- (2)
- (1)
- (2)
- (3)
- (2)
- (2)
- (5)
- (3)
- (2)
- (2)
- (1)
- (4)
- (3)
- (1)
- (1)
- (2)
- (2)
- (3)
- (2)
- (2)
- (3)
- (2)
- (1)
- (1)
- (5)
- (1)
- (2)
- (5)
- (5)
- (2)
- (1)
- (1)
- (2)
- (2)
- (1)
- (1)
- (7)
- (2)
- (2)
- (1)
- (3)
- (1)
- (3)
- (2)
- (5)
- (2)
- (2)
- (2)
- (2)
- (5)
- (2)
- (1)
- (6)
- (3)
- (2)
- (1)
- (5)
- (5)
- (2)
- (2)
- (1)
- (6)
- (1)
- (1)
- (1)
- (1)
- (5)
- (1)
- (2)
- (4)
- (1)
- (3)
- (1)
- (1)
- (2)
- (1)
- (1)
- (2)
- (1)
- (1)
- (1)
- (1)
- (2)
- (1)
- (1)
- (2)
- (2)
- (1)
- (2)
- (1)
- (1)
- (5)
- (2)
- (2)
- (1)
- (1)
- (2)
- (8)
- (4)
- (14)
- (7)
- (8)
- (1)
- (3)
- (1)
- (6)
- (1)
- (1)
- (5)
- (2)
- (1)
- (1)
- (2)
- (20)
- (4)
- (5)
- (1)
- (3)
- (2)
- (1)
- (7)
- (8)
- (7)
- (2)
- (1)
- (2)
- (1)
- (3)
- (5)
- (5)
- (1)
- (3)
- (1)
- (3)
- (6)
- (3)
- (3)
- (1)
- (2)
- (26)
- (54)
- (5)
- (11)
- (4)
- (6)
- (6)
- (16)
- (1)
- (129)
- (3)
- (1)
- (2)
- (5)
- (4)
- (14)
- (38)
- (3)
- (13)
- (12)
- (7)
- (1)
- (6)
- (6)
- (6)
- (1)
- (1)
- (1)
- (1)
- (1)
- (12)
- (38)
- (5)
- (1)
- (2)
- (1)
- (1)
- (12)
- (2)
- (15)
- (1)
- (1)
- (1)
- (1)
- (1)
- (1)
- (1)
- (1)
- (6)
- (15)
- (2)
- (1)
- (19)
- (3)
- (18)
- (1)
- (1)
- (1)
- (1)
- (2)
- (1)
- (29)
- (3)
- (2)
- (1)
- (2)
- (1)
- (1)
- (6)
- (1)
- (1)
- (1)
- (1)
- (44)
- (2)
- (27)
- (1)
- (73)
- (6)
- (73)
Filtered Search Results
Salbutamol impurity I Pharmaceutical Secondary Standard, MilliporeSigma™ Supelco™
Salbutamol impurity I is a pharmaceutical impurity of salbutamol, belonging to the class of β2-agonists, widely used for the treatment of acute asthma symptoms and exercise-induced asthma in adults and children.
Chloroquine phosphate Pharmaceutical Secondary Standard, MilliporeSigma™ Supelco™
Pharmaceutical secondary standards for application in quality control, provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards.
Vecuronium Bromide Pharmaceutical Secondary Standard, MilliporeSigma™ Supelco™
Vecuronium Bromide is a nondepolarizing neuromuscular blocking agent, which helps for adequate muscle relaxation for all types of surgical procedures in the absence of cardiorespiratory depressant effects of deep anesthesia.
Sorbitol, Pharmaceutical Secondary Standard, Certified Reference Material, MilliporeSigma™ Supelco™
Certified pharmaceutical secondary standards for application in quality control provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to pharmacopeia primary standards
Ciprofloxacin Related Compound A Pharmaceutical Secondary Standard, MilliporeSigma™ Supelco™
Pharmaceutical secondary standards for application in quality control provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards
Hydroxyproline Pharmaceutical Secondary Standard, MilliporeSigma™ Supelco™
Pharmaceutical secondary standards for application in quality control provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards
Repaglinide 98.0+%, TCI America™
CAS: 135062-02-1 Molecular Formula: C27H36N2O4 Molecular Weight (g/mol): 452.60 MDL Number: MFCD00906179 InChI Key: FAEKWTJYAYMJKF-QHCPKHFHSA-N Synonym: (S)-(+)-2-Ethoxy-4-[N-[1-(2-piperidinophenyl)-3-methyl-1-butyl]aminocarbonylmethyl]benzoic Acid PubChem CID: 65981 ChEBI: CHEBI:8805 IUPAC Name: 2-ethoxy-4-({[(1S)-3-methyl-1-[2-(piperidin-1-yl)phenyl]butyl]carbamoyl}methyl)benzoic acid SMILES: CCOC1=CC(CC(=O)N[C@@H](CC(C)C)C2=CC=CC=C2N2CCCCC2)=CC=C1C(O)=O
| PubChem CID | 65981 |
|---|---|
| CAS | 135062-02-1 |
| Molecular Weight (g/mol) | 452.60 |
| ChEBI | CHEBI:8805 |
| MDL Number | MFCD00906179 |
| SMILES | CCOC1=CC(CC(=O)N[C@@H](CC(C)C)C2=CC=CC=C2N2CCCCC2)=CC=C1C(O)=O |
| Synonym | (S)-(+)-2-Ethoxy-4-[N-[1-(2-piperidinophenyl)-3-methyl-1-butyl]aminocarbonylmethyl]benzoic Acid |
| IUPAC Name | 2-ethoxy-4-({[(1S)-3-methyl-1-[2-(piperidin-1-yl)phenyl]butyl]carbamoyl}methyl)benzoic acid |
| InChI Key | FAEKWTJYAYMJKF-QHCPKHFHSA-N |
| Molecular Formula | C27H36N2O4 |
Pemetrexed Hydrate 98.0+%, TCI America™
CAS: 137281-23-3 Molecular Formula: C20H21N5O6 Molecular Weight (g/mol): 427.417 MDL Number: MFCD19105065 InChI Key: WBXPDJSOTKVWSJ-ZDUSSCGKSA-N Synonym: N-[4-[2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic Acid PubChem CID: 446556 ChEBI: CHEBI:63616 IUPAC Name: (2S)-2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioic acid SMILES: C1=CC(=CC=C1CCC2=CNC3=C2C(=O)N=C(N3)N)C(=O)NC(CCC(=O)O)C(=O)O
| PubChem CID | 446556 |
|---|---|
| CAS | 137281-23-3 |
| Molecular Weight (g/mol) | 427.417 |
| ChEBI | CHEBI:63616 |
| MDL Number | MFCD19105065 |
| SMILES | C1=CC(=CC=C1CCC2=CNC3=C2C(=O)N=C(N3)N)C(=O)NC(CCC(=O)O)C(=O)O |
| Synonym | N-[4-[2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic Acid |
| IUPAC Name | (2S)-2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioic acid |
| InChI Key | WBXPDJSOTKVWSJ-ZDUSSCGKSA-N |
| Molecular Formula | C20H21N5O6 |
Penciclovir 98.0+%, TCI America™
CAS: 39809-25-1 Molecular Formula: C10H15N5O3 Molecular Weight (g/mol): 253.262 MDL Number: MFCD15142866 InChI Key: JNTOCHDNEULJHD-UHFFFAOYSA-N Synonym: BRL 39123, 2-Amino-9-[4-hydroxy-3-(hydroxymethyl)butyl]-1H-purin-6-one, 9-[4-Hydroxy-3-(hydroxymethyl)butyl]guanine PubChem CID: 4725 ChEBI: CHEBI:7956 IUPAC Name: 2-amino-9-[4-hydroxy-3-(hydroxymethyl)butyl]-3H-purin-6-one SMILES: C1=NC2=C(N1CCC(CO)CO)NC(=NC2=O)N
| PubChem CID | 4725 |
|---|---|
| CAS | 39809-25-1 |
| Molecular Weight (g/mol) | 253.262 |
| ChEBI | CHEBI:7956 |
| MDL Number | MFCD15142866 |
| SMILES | C1=NC2=C(N1CCC(CO)CO)NC(=NC2=O)N |
| Synonym | BRL 39123, 2-Amino-9-[4-hydroxy-3-(hydroxymethyl)butyl]-1H-purin-6-one, 9-[4-Hydroxy-3-(hydroxymethyl)butyl]guanine |
| IUPAC Name | 2-amino-9-[4-hydroxy-3-(hydroxymethyl)butyl]-3H-purin-6-one |
| InChI Key | JNTOCHDNEULJHD-UHFFFAOYSA-N |
| Molecular Formula | C10H15N5O3 |
Rosiglitazone 98.0+%, TCI America™
CAS: 122320-73-4 Molecular Formula: C18H19N3O3S Molecular Weight (g/mol): 357.43 MDL Number: MFCD00871760 InChI Key: YASAKCUCGLMORW-UHFFFAOYNA-N PubChem CID: 77999 ChEBI: CHEBI:50122 IUPAC Name: 5-[(4-{2-[methyl(pyridin-2-yl)amino]ethoxy}phenyl)methyl]-1,3-thiazolidine-2,4-dione SMILES: CN(CCOC1=CC=C(CC2SC(=O)NC2=O)C=C1)C1=CC=CC=N1
| PubChem CID | 77999 |
|---|---|
| CAS | 122320-73-4 |
| Molecular Weight (g/mol) | 357.43 |
| ChEBI | CHEBI:50122 |
| MDL Number | MFCD00871760 |
| SMILES | CN(CCOC1=CC=C(CC2SC(=O)NC2=O)C=C1)C1=CC=CC=N1 |
| IUPAC Name | 5-[(4-{2-[methyl(pyridin-2-yl)amino]ethoxy}phenyl)methyl]-1,3-thiazolidine-2,4-dione |
| InChI Key | YASAKCUCGLMORW-UHFFFAOYNA-N |
| Molecular Formula | C18H19N3O3S |
Rosuvastatin Calcium 95.0+%, TCI America™
CAS: 147098-20-2 Molecular Formula: C44H60CaF2N6O12S2 Molecular Weight (g/mol): 1007.189 MDL Number: MFCD04112702 InChI Key: LQFSLFAVBQEFBH-LSMDDVBQSA-N PubChem CID: 131673834 IUPAC Name: calcium;(E,3R,5S)-7-[4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-propan-2-ylpyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid;molecular hydrogen SMILES: [HH].[HH].CC(C)C1=NC(=NC(=C1C=CC(CC(CC(=O)O)O)O)C2=CC=C(C=C2)F)N(C)S(=O)(=O)C.CC(C)C1=NC(=NC(=C1C=CC(CC(CC(=O)O)O)O)C2=CC=C(C=C2)F)N(C)S(=O)(=O)C.[Ca]
| PubChem CID | 131673834 |
|---|---|
| CAS | 147098-20-2 |
| Molecular Weight (g/mol) | 1007.189 |
| MDL Number | MFCD04112702 |
| SMILES | [HH].[HH].CC(C)C1=NC(=NC(=C1C=CC(CC(CC(=O)O)O)O)C2=CC=C(C=C2)F)N(C)S(=O)(=O)C.CC(C)C1=NC(=NC(=C1C=CC(CC(CC(=O)O)O)O)C2=CC=C(C=C2)F)N(C)S(=O)(=O)C.[Ca] |
| IUPAC Name | calcium;(E,3R,5S)-7-[4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-propan-2-ylpyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid;molecular hydrogen |
| InChI Key | LQFSLFAVBQEFBH-LSMDDVBQSA-N |
| Molecular Formula | C44H60CaF2N6O12S2 |